Mark my words... ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

AN OXFORD CLUB PUBLICATION

View in browser SPONSORED Nvidia's BIG AI Biotech Bet An under-the-radar $10 biotech company is on the verge of a game-changing AI breakthrough. So much so, that Nvidia has staked a MAJOR claim on its future success. And at an exclusive upcoming event, Marc Lichtenfeld will reveal how you could turn a small stake into a potential 550% windfall in just 6 months... Claim a free spot to attend right here. Editor's Note: Artificial intelligence and biotech have been on Chief Income Strategist Marc Lichtenfeld's mind a lot lately... And he's just found a stock that he believes is a phenomenal way to get exposure to both. Even better, the company has a huge announcement coming as soon as July 1 that could send shares soaring... Learn more by reserving your spot at his free event next Thursday. - James Ogletree, Managing Editor MARKET TRENDS This Powerful Alliance Could Reshape the Global Economy Marc Lichtenfeld, Chief Income Strategist, The Oxford Club Are you familiar with Moore's law? It states that the number of transistors on a microchip doubles about every two years. This leads to increased computing power and lower costs, driving rapid advancements in technology. You can look back over 50 years and see this pattern play out... View larger image   But Moore's law has an evil twin... Eroom's law ("Moore" spelled backward). It says that the cost of developing new drugs roughly doubles every nine years despite all of these advancements in technology. So the more money we spend, the fewer drugs we find! View larger image   As it stands now, 90% of drugs fail clinical trials. Discovery and development can take up to 16 years, and it costs as much as $2 billion to bring a drug to market. But, folks, at long last... after DECADES of this frustrating law holding true... it looks like we're finally turning a corner. The hero? SPONSORED AI DIVIDENDS: No. 1 Way to Collect Passive Income Right now, a handful of AI companies are paying passive income to investors... And getting started couldn't be easier! To prove it, I'm giving you my Free AI Income Playbook (FREE OF CHARGE). Click here to get it for free. Artificial intelligence. AI can analyze large datasets to identify potential drug targets... It can design novel drug-like molecules from scratch... It can optimize clinical trials... And it can do a whole lot more. The end result? Not only faster, cheaper and more effective drugs... but an absolute windfall for smart investors who get positioned ahead of this revolution. When all is said and done, experts predict that by 2040, generative AI could result in $1 trillion in value for healthcare. European fund manager Hans Peter Portner expects biotech stocks to get swept into this next phase of AI euphoria after missing out on the first leg (which means the upside could be INSANE). Mark my words... THIS is where AI will have the biggest economic impact... and where early investors can make a killing. But how? And where? That's what you'll discover on June 27 at 2 p.m. ET during my exclusive live broadcast (it's free to attend!). I can't give too much away now... But for fun, I'll give you a few brief hints. I'll be focusing on one particular stock that's trading for less than $10... It's a fairly young company... And if the CEO is right, its technology will get drugs into trials after just one or two years... and for just $10 million to $20 million! Now THAT would be truly game-changing. On June 27, I'll tell you more about the unique way I plan on playing this powerful alliance for potential maximum gains. Just make sure you don't miss out. This small company is about to make an announcement that could be truly groundbreaking. After you claim your seat at this free event, you'll receive several more updates over the next few days, including more details on why I'm so bullish on this company and how I came to be an expert on trading stock catalysts like the company's upcoming announcement. I hope you'll join me next Thursday. I'm confident you won't regret it. Go here to reserve your spot. Good investing, Marc Leave a Comment BUILD AND PROTECT YOUR WEALTH This uber-successful hedge fund CEO has been investing since he was 12... and these are HIS THREE picks for 2024's top stocks The Key to Finding Winners in the AI Craze Top Trader Reveals "One Ticker Payouts": One Ticker... One Trade... Every Week! Steer Clear of This Investment MORE FROM WEALTHY RETIREMENT How AI and Biotech Could Reshape the Global Economy Globe Life: Tarnished Insurance Giant... or Undervalued Gem? Broadcom: A Semiconductor Superstar With a Safe Dividend The Overlooked Opportunity for Value Investors in 2024 Facebook LinkedIn Email Share Push Alert SPONSORED Putin's Spiteful Behavior Could Make Americans Rich??   Source: www.kremlin.ru   One company is already generating record profits. In fact, Wall Street projects one $30 stock will rise to $280 in just 18 months... all thanks to a HUGE mistake by Russia's president. Here's what you need to know... You are receiving this email because you subscribed to Wealthy Retirement. Wealthy Retirement is published by The Oxford Club. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Privacy Policy | Whitelist Wealthy Retirement | Unsubscribe © 2024 The Oxford Club, LLC All Rights Reserved The Oxford Club | 105 West Monument Street | Baltimore, MD 21201 North America: 877.808.9795 | International: +1.443.353.4621 Oxfordclub.com Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201.